Ozempic is a semaglutide GLP-1 analog used for type 2 diabetes and cardio-renal risk reduction in appropriate adults. It is administered as a once-weekly injection, and tablet formulations are also listed under the Ozempic brand. The FDA first approved Ozempic on December 5, 2017.
The White House reports a 3.1% drop in prescription drug prices over the past year, the steepest decline since 1963, attributing it to President Trump's Most Favored Nation policies and TrumpRx discounts. Drugmakers like Pfizer have agreed to significant price cuts on several medications.
UK data links 150+ deaths to weight-loss jabs. A new study finds a vegan diet led to 5.9kg average loss in 4 months vs 6.9kg over 9 months for semaglutide.
Physician-supervised clinics in Florida and Texas offer semaglutide and tirzepatide weight loss programs. Clinical trials show average weight loss of 15% with semaglutide and about 21% with tirzepatide. All-inclusive monthly plans start at $349.
Lupin reported record Q3 FY2026 revenue of INR 7,168 crores and a 31.1% EBITDA margin, while preparing to launch a generic semaglutide and shifting focus to innovation. The company also secured US FDA approval for Pegfilgrastim and EU approval for ranibizumab biosimilar.
Adding bacteriostatic water to a 3mg semaglutide vial changes its concentration; the correct amount depends on the pharmacy's specification. FDA-approved semaglutide pens should not be reconstituted. The FDA has received reports of hospitalizations linked to compounded semaglutide dosing errors.
Orforglipron beat oral semaglutide on blood sugar and weight in type 2 diabetes, with higher discontinuation rates. GLP-1 hair loss is typically temporary telogen effluvium.
Blockbuster drugs worth hundreds of billions face generic competition as patents expire through 2032. Indian drugmakers could capture $3-5 billion of the opportunity, while GSK and Bristol Myers Squibb prepare for revenue losses.
Semaglutide may lower risks of adult-onset seizures and alcohol-related hospitalizations, new studies find. Brazil approved five semaglutide injectables, and a commentary updates obesity care with GLP-1 drugs.
Pharmaceutical manufacturers are shifting to greener production methods for GLP-1 peptide weight-loss drugs like Ozempic and Wegovy, reducing reagent waste and moving away from restricted solvents. The traditional process uses up to 13,000 kg of reagents per kg of peptide. Expert Fernando Albericio also calls for ethical use of these medications, often dubbed 'Hollywood drugs.'
GLP-1 receptor agonists are linked to a higher risk of smell and taste disturbances, while poison control calls involving semaglutide have soared since 2021. The drugs produce significant weight loss and are reshaping U.S. food demand, with roughly one in eight adults now taking them.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07046273 |
Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes |
NOT_YET_RECRUITING | PHASE3 |
| NCT06967389 |
Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity |
RECRUITING | |
| NCT06739044 |
Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes |
COMPLETED | PHASE3 |
| NCT06634927 |
Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects. |
COMPLETED | PHASE1 |
| NCT06161844 |
Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus |
COMPLETED | PHASE3 |
| NCT04572165 |
Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data |
COMPLETED |
